Metronomic chemotherapy offers hope for children with neuroblastoma
Despite advances in treatment, survival rates for high-risk and relapsed/refractory neuroblastoma remain dismal, and options like autologous stem cell transplantation and immunotherapy are frequently unavailable in low- and middle-income countries. Given these stark realities, there is a critical need for alternative, more accessible therapies like metronomic chemotherapy (MC) to improve survival prospects for these children.
Comentários